Search Results

Press Releases

Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States

Fiscal Q3 2025 revenue of $30.0 million, net income of $0.7 million, operating income of $3.8 million, and Adjusted EBITDA* of $5.8 million Management to host conference call at 8:00 AM Eastern time on Thursday, February 6, 2024

February 6, 2025

·

24 min read

Trendy halftone business concept collage. Idea concept, business concept, financial planning,financial profit, favorable conditions, favorable conditions. Trendy modern retro illustration in bright trendy colors. Vector illustration

Mergers & acquisitions

Bain Bets Big on Japanese Market With $3.3B Tanabe Buy

The carve-out acquisition will allow Bain to capitalize on the “promising signs for growth” in the Japanese life sciences market, recently revitalized by more industry-friendly policy changes from the government.

February 10, 2025

·

1 min read

·

Tristan Manalac

Pictured: Eli Lilly's headquarters in Indianapolis

Deals

Lilly Drops Up to $2.5B for Scorpion’s PI3K-inhibitor Molecule

The multi-billion deal, in which Eli Lilly will acquire Scorpion Therapeutics’ STX-478 program, is a shot in the arm for PI3K treatments, which have had a mixed history over the past few years.

January 13, 2025

·

2 min read

·

Dan Samorodnitsky

3 Major Product Releases at 3Shape Discover Event

3Shape announces the launch of three exciting solutions at its 3Shape Discover digital dentistry event.

June 7, 2024

·

3 min read

Approvals

Roche Wins First-Line Breast Cancer Nod for Oral PI3K Blocker, Projects $2.3B in Peak Sales

With the regulatory approval for advanced breast cancer, Roche’s inavolisib is a potential challenger to Novartis’ PI3K inhibitor Piqray, which last year generated $505 million in revenue.

October 11, 2024

·

2 min read

·

Tristan Manalac